Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 03, 2026
Iterum files wind-up petition due to limited cash, inability to raise equity
10:41am, Friday, 27'th Mar 2026
Iterum Therapeutics said on Friday it has filed a petition in Ireland's High Court to wind up the drugmaker and was placed into provisional liquidation, with a hearing set for April 13.
Iterum Therapeutics Announces Filing of Winding Up Petition
09:25am, Friday, 27'th Mar 2026
DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on deliver
Iterum Therapeutics Provides Business Update
08:00am, Friday, 13'th Feb 2026
--Expanded Market Access and Patent Protection for ORLYNVAH™ --FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum
Iterum Therapeutics Provides Business Update
08:00am, Tuesday, 23'rd Dec 2025
DUBLIN and CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and I
Iterum Therapeutics Provides Business Update
08:00am, Wednesday, 17'th Dec 2025
DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and I
Iterum Therapeutics Provides Business Update
08:00am, Friday, 05'th Dec 2025
DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and I
Iterum Therapeutics Provides Business Update
08:00am, Monday, 24'th Nov 2025
DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV a
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
11:11am, Friday, 14'th Nov 2025
Iterum Therapeutics plc ( ITRM ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Kevin Dalton Corey Fishman - President, CEO & Director Christine Coyne - Chief Commercial Offi
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
07:00am, Friday, 14'th Nov 2025
- -Commercially Launched ORLYNVAH ™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
08:00am, Friday, 07'th Nov 2025
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infect
Iterum Therapeutics to Present Data at IDWeek 2025
08:30am, Tuesday, 14'th Oct 2025
DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections
Iterum Therapeutics Provides Business Update
08:00am, Friday, 19'th Sep 2025
DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caus
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
08:00am, Wednesday, 20'th Aug 2025
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections FDA-approved antibiotic with the power o
Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript
04:58pm, Tuesday, 05'th Aug 2025
Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Corey N. Fishman - President, CEO & Director Judith M.
